COMPARE · Data as of August 24, 2026
BHC vs PAHC
Verdict: Side-by-side breakdown using the Bull Rankings model. BHC scored 71.3, PAHC scored 72.1 — PAHC leads.
Compare another set
BHC
Bausch Health Companies Inc.
71.3
$6.68 · $2.5B
fundamentals as of
Score gap
0.8
PAHC leads
PAHC
Phibro Animal Health Corp
72.1
$35.31 · $1.4B
At a glance · who leads each dimension, on the model's own rules
- Fastest growthPAHC+26.0%
- Highest qualityBHC63 / 100
- Largest discount to fair valueBHC-86%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
BHC
stronger →← stronger
PAHC
63
Qualityreturns · margins · balance sheet
61
64
Growthrevenue & earnings expansion
86
91
Valuevaluation vs sector peers
71
BHC is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
BHC
PAHC
$1.4bC+
FCF
$13mC-
+10.1%B
Rev
+26.0%A-
—
D/E
2.52D+
0.2xA
P/S
—
0.01A
PEG
—
—
P/E
14.5xB+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
BHC
PAHC
86% below
Price vs fair valuelower is cheaper
378% above
decline
Growth the price implies10-yr FCF · lower = less priced in
~58%/yr
+677%
1-yr DCF upside
-84%
+599%
5-yr DCF upside
-79%
+504%
10-yr DCF upside
-69%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
BHC
PAHC
No notable signals flagged.
The companies
BHCBausch Health Companies Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $2.5b. 17% off the 52-week high of $8.00. Revenue growing +10%, comfortably above the S&P median. PEG 0.01 — paying under fair value for the growth rate. 5 sell-side analysts publish a mean 1-yr target of $7.50 (implying +12% upside).
Moat
ROE 62% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -10.1%) — path to GAAP profitability is the core thesis risk. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
PAHCPhibro Animal Health Corp
Why now
Pharmaceuticals · market cap $1.4b. Down 41% from 52-week high of $60.08 — deep drawdown territory. Revenue growing +26% — in hypergrowth territory.
Moat
ROE 29% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.52 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 41% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where BHC and PAHC diverge
On the headline score the gap is 0.8 points in favor of PAHC. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- GrowthBHC 63.7 · PAHC 85.6PAHC +21.9
- ValueBHC 90.6 · PAHC 71.3BHC +19.3
- QualityBHC 62.9 · PAHC 61.4level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.